PDF(680 KB)
PDF(680 KB)
PDF(680 KB)
影响西罗莫司药动学、疗效及不良反应的因素分析
Analysis of influencing factors for pharmacokinetics, therapeutic efficacy and adverse effects of sirolimus
目的:分析各影响西罗莫司的体内药动学参数、临床疗效及不良反应的因素,为临床个体化用药提供参考。方法:通过国内外文献分析,归纳个体差异、患者状态、共服药物及用药方案等因素对西罗莫司药动学参数、临床疗效及不良反应的影响。结果:西罗莫司的治疗窗窄、个体差异化大,可致高脂血症、贫血、白细胞及血小板减少等不良反应。结论:多种因素共同影响西罗莫司的临床应用,需综合考虑以实现个体化用药及确保用药安全。
OBJECTIVE To analyze factors that affected pharmacokinetic parameters, therapeutic efficacy and adverse effects of sirolimus for clinical personalized medication. METHODS Influencing factors like individual differences, patient conditions, coadministration and therapeutic regimens were concluded through referring to a great quantity of internal and overseas literatures. RESULTS CONCLUSION Various factors can affect clinical use of sirolimus, and all of these factors should be taken into account to realize individualized medication and to ensure medication safety.
西罗莫司 / 药动学 / 疗效 / 不良反应 / 影响因素 {{custom_keyword}} /
sirolimus / pharmacokinetics / therapeutic efficacy / adverse effects / influencing factors {{custom_keyword}} /
[1] MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
[J]. Clin Ther, 2000, 22 Suppl B: B101-B121.
[2] Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients
[J].Clin Pharmacokinet, 2006, 45(11): 1135-1148.
[3] 牟静, 傅晓华, 任斌, 等.西罗莫司治疗肾移植后排斥反应的疗效, 不良反应与其血药浓度的相关性分析
[J]. 中国药房, 2011, 22(30): 2839-2841.
[4] Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity
[J]. Clin Transplant, 2000, 14(2): 97-109.
[5] Woillard JB, Kamar N, Rousseau A, et al. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients
[J]. Pharmacogenet Genomics, 2012, 22(10): 725-732.
[6] Reichen J, Stickel F, Bhattacharya I, et al. Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts
[J]. Eur J Clin Pharmacol, 2012, 68(5): 589-597.
[7] Sam WJ, Chamberlain CE, Lee SJ, et al. Associations of ABCB1 3435C> T and IL-10-1082G> A polymorphisms with long-term sirolimus dose requirements in renal transplant patients
[J]. Transplantation, 2011, 92(12): 1342-1347.
[8] Lee J, Huang H, Chen Y, et al. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients
[J]. Biopharm Drug Dispos, 2014 , 35(3):164-172.
[9] Sam WJ, Chamberlain CE, Lee SJ, et al. Associations of ABCB1 and IL-10 Genetic Polymorphisms With Sirolimus-Induced Dyslipidemia in Renal Transplant Recipients
[J]. Transplantation, 2012, 94(9): 971-977.
[10] Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy
[J]. Am J Transplant, 2005, 5(3): 595-603.
[11] Zimmerman JJ, Patat A, Parks V, et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with severe hepatic impairment
[J]. J Clin Pharmacol, 2008, 48(3): 285-292.
[12] Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens
[J]. Transplant Proc, 2011, 43(5): 1583-1592.
[13] Massoud O, Wiesner RH. The use of Sirolimus should be restricted in liver transplantation
[J]. J Hepatol, 2012, 56(1): 288-290.
[14] Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial
[J]. Am J Transplant, 2012, 12(3): 694-705.
[15] Agarwal PD, Lucey MR. Sirolimus: More cause for alarm?
[J].Liver Transpl, 2012, 18(9): 1003-1004.
[16] Rial Medl C, Abbud-Filho M, Torres Gonoalves RT, et al. Individualizing early use of sirolimus in renal transplantation
[J]. Transplant Proc, 2010, 42(10): 4518-4525.
[17] Perrakis A, Schwarz K, Yedibela S, et al. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome
[J]. Transplant Proc, 2011, 43(10): 3702-3707.
[18] 许世磊, 张英才, 易慧敏, 等.西罗莫司应用于肝癌肝移植受者的疗效分析
[J]. 中华器官移植杂志, 2013, 34(8): 481-485.
[19] Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?
[J]. Ann Pharmacother, 2008, 42(7):1037-47.
[20] Robert W. Steiner, Linda Awdishu. Steroids in kidney transplant patients
[J]. Semin Immunopathol, 2011, 33(2): 157-167.
[21] Tortorici MA, Parks V, Matschke K, et al. The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers
[J]. Eur J Clin Pharmacol, 2013, 69(4): 835-842.
[22] Baldan N, Rigotti P, Furian L, et al. Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients
[J]. Pharmacol Res, 2006, 54(3): 181-185.
[23] Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus
[J]. The AAPS J, 2004, 6(4): 1-12.
[24] O’Connell S, Slattery C, Ryan MP, et al. Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells
[J]. J Transplant, 2012, 2012: 980910.
[25] Haggan W, Ficheux M, Debruyne D, et al. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine
[J]. Transplant Proc, 2005, 37(2): 864-866.
[26] Lebranchu Y, Thierry A, Thervet E, et al. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study
[J]. Am J Transplant, 2011, 11(8): 1665-1675.
[27] Tortorici MA, Matschke K, Korth-Bradley JM, et al. The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers
[J]. Clinical Pharmacology in Drug Development, 2014, 3(1): 51-56.
[28] Masters JC, Shah MM, Feist AA. Drug Interaction between Sirolimus and Ranolazine in a Kidney Transplant Patient
[J]. Case Rep Transplant, 2014, 2014:548243.
[29] Caballero-Velázquez T, Sánchez-Abarca LI, Gutierrez-Cosio S, et al. The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation
[J]. Haematologica, 2012, 97(9): 1329-1337.
[30] Deters M, Hütten H, Kaever V. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin
[J]. Phytomedicine, 2013, 20(2): 120-123.
[31] Li R, Guo W, Fu Z, et al. A study about drug combination therapy of Schisandra sphenanthera extract and Rapamycin in healthy subjects
[J]. Canadian Journal of Physiology and Pharmacology, 2012, 90(7): 941-945.
[32] Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, et al. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
[J]. Int J Cardiol, 2014, 171(1): 15-23.
[33] Kasiske BL, Nashan B, Del Carmen Rial M, et al. A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation
[J]. J Transplant, 2012, 2012:107180.
[34] Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial
[J]. Transplantation, 2009, 87(2): 233-242.
[35] 田晓辉, 薛武军, 田普训, 等.钙调磷酸酶抑制剂转换为西罗莫司治疗慢性移植物肾病的疗效研究
[J]. 器官移植, 2013, 3(6): 320-323.
[36] 夏盛强, 范昱, 邱建新, 等.将钙调磷酸酶抑制剂转换为西罗莫司在慢性移植肾肾病中的临床治疗效果
[J]. 中华器官移植杂志, 2013, 34(3): 163-166.
/
| 〈 |
|
〉 |
